Drugs / Darotamide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05406999 | Feb 2020 → Dec 2026 expected | prostate cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Darotamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05406999 ↗ |
| Route | Oral | “600 mg (300 mg × 2 tablets) twice daily, orally.” NCT05406999 ↗ |